KR100839766B1 - 신경통 및 정동 또는 주의력 장애 치료용 플루오르화트리아졸의 용도 - Google Patents
신경통 및 정동 또는 주의력 장애 치료용 플루오르화트리아졸의 용도 Download PDFInfo
- Publication number
- KR100839766B1 KR100839766B1 KR1020077029858A KR20077029858A KR100839766B1 KR 100839766 B1 KR100839766 B1 KR 100839766B1 KR 1020077029858 A KR1020077029858 A KR 1020077029858A KR 20077029858 A KR20077029858 A KR 20077029858A KR 100839766 B1 KR100839766 B1 KR 100839766B1
- Authority
- KR
- South Korea
- Prior art keywords
- disorder
- medicament
- medicament according
- formula
- treatment
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 24
- 208000035475 disorder Diseases 0.000 title claims abstract description 24
- 208000002193 Pain Diseases 0.000 title abstract description 19
- 150000003852 triazoles Chemical class 0.000 title abstract description 5
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 208000020925 Bipolar disease Diseases 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 36
- 208000019022 Mood disease Diseases 0.000 claims description 8
- 230000003542 behavioural effect Effects 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 206010037180 Psychiatric symptoms Diseases 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 208000008811 Agoraphobia Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 230000036651 mood Effects 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims 3
- 230000037444 atrophy Effects 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 1
- 208000037870 generalized anxiety Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000006201 parenteral dosage form Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 abstract description 11
- 208000004454 Hyperalgesia Diseases 0.000 abstract description 8
- 208000035154 Hyperesthesia Diseases 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 6
- 230000006399 behavior Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- -1 2,5-difluorophenyl Chemical group 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000010271 Heart Block Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091002531 OF-1 protein Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940127558 rescue medication Drugs 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (35)
- 제1항에 있어서, 화학식 I의 화합물이 1-(2,6-디플루오로페닐)메틸-1H-1,2,3-트리아졸-4-카르복스아미드인 의약.
- 제1항 또는 제2항에 있어서, 정동 장애 치료용인 의약.
- 제1항 또는 제2항에 있어서, 양극성 장애 치료용인 의약.
- 제1항 또는 제2항에 있어서, 양극성 기분 장애 치료용인 의약.
- 제1항 또는 제2항에 있어서, 극단적인 정신병적 상태 치료용인 의약.
- 제1항 또는 제2항에 있어서, 조울정신증 치료용인 의약.
- 제1항 또는 제2항에 있어서, 조증 치료용인 의약.
- 제1항 또는 제2항에 있어서, 정신분열증 치료용인 의약.
- 제1항 또는 제2항에 있어서, 거동 안정화가 요구되는 과도한 기분 동요 치료용인 의약.
- 제1항 또는 제2항에 있어서, 우울증 및 관련 정신의학적 증상이 특징인 사회적 위축증 치료용인 의약.
- 제1항 또는 제2항에 있어서, 항우울제-유사 용도로 사용하기 위한 의약.
- 제1항 또는 제2항에 있어서, 우울증과 관련된 정신의학적 증상이 특징인 사회적 위축증 치료용인 의약.
- 제1항 또는 제2항에 있어서, 장애가 주의력 장애인 의약.
- 제1항 또는 제2항에 있어서, 장애가 주의력 결핍 과다활동 장애(ADHD) 및 다른 주의력 장애로 이루어진 군으로부터 선택된 것인 의약.
- 제15항에 있어서, 장애가 주의력 결핍 과다활동 장애(ADHD)인 의약.
- 제15항에 있어서, 장애가 주의력 결핍 과다활동 장애(ADHD) 이외의 주의력 장애인 의약.
- 제1항 또는 제2항에 있어서, 장애가 자폐증인 의약.
- 제1항 또는 제2항에 있어서, 장애가 불안 상태인 의약.
- 제1항 또는 제2항에 있어서, 장애가 범불안증인 의약.
- 제1항 또는 제2항에 있어서, 장애가 광장공포증인 의약.
- 제1항 또는 제2항에 있어서, 장애가 사회적 위축증을 특징으로 하는 거동 상태인 의약.
- 제1항 또는 제2항에 있어서, 장애가 무증상인 의약.
- 제1항 또는 제2항에 있어서, 의약의 1일 투여량이 체중 1 kg당 화학식 I의 화합물 1 내지 50 mg인 의약.
- 제1항 또는 제2항에 있어서, 인간에 대한 의약의 1일 투여량이 화학식 I의 화합물 50 내지 3500 mg인 의약.
- 제1항 또는 제2항에 있어서, 의약의 1일 투여량을 4회 이상 분할된 투여량으로 투여하는 의약.
- 제1항 또는 제2항에 있어서, 경구 투여형인 의약.
- 제27항에 있어서, 정제인 의약.
- 제27항에 있어서, 캡슐인 의약.
- 제1항 또는 제2항에 있어서, 비경구 투여형인 의약.
- 제30항에 있어서, 주사 용액인 의약.
- 제30항에 있어서, 주사 현탁액인 의약.
- 제1항 또는 제2항에 있어서, 화학식 I의 화합물을 10 내지 1500 mg 함유하는 단위 투여형인 의약.
- 제33항에 있어서, 정제형인 의약의 투여량이 50 mg의 제2항의 화학식 I의 화합물인 의약.
- 제33항에 있어서, 필름-코팅 정제형인 의약의 투여량이 100 mg의 제2항의 화학식 I의 화합물인 의약.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/259,910 | 1999-03-01 | ||
US09/259,911 | 1999-03-01 | ||
US09/259,910 US6156775A (en) | 1999-03-01 | 1999-03-01 | Use of fluorinated triazoles in treating affective and attention disorders |
US09/259,911 US6054471A (en) | 1999-03-01 | 1999-03-01 | Use of fluorinated triazoles in treating neuropathic pain |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017011098A Division KR100839765B1 (ko) | 1999-03-01 | 2000-02-28 | 신경통 및 정동 또는 주의력 장애 치료용 플루오르화트리아졸의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080003944A KR20080003944A (ko) | 2008-01-08 |
KR100839766B1 true KR100839766B1 (ko) | 2008-06-20 |
Family
ID=26947613
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017011098A KR100839765B1 (ko) | 1999-03-01 | 2000-02-28 | 신경통 및 정동 또는 주의력 장애 치료용 플루오르화트리아졸의 용도 |
KR1020077029858A KR100839766B1 (ko) | 1999-03-01 | 2000-02-28 | 신경통 및 정동 또는 주의력 장애 치료용 플루오르화트리아졸의 용도 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017011098A KR100839765B1 (ko) | 1999-03-01 | 2000-02-28 | 신경통 및 정동 또는 주의력 장애 치료용 플루오르화트리아졸의 용도 |
Country Status (25)
Country | Link |
---|---|
EP (2) | EP1609505B1 (ko) |
JP (1) | JP4700195B2 (ko) |
KR (2) | KR100839765B1 (ko) |
CN (2) | CN1636562A (ko) |
AT (1) | ATE303179T1 (ko) |
AU (1) | AU764508B2 (ko) |
BR (1) | BR0008606A (ko) |
CA (1) | CA2362411C (ko) |
CY (1) | CY1115241T1 (ko) |
DE (1) | DE60022317T2 (ko) |
DK (2) | DK1156856T3 (ko) |
ES (2) | ES2244413T3 (ko) |
HK (1) | HK1086775A1 (ko) |
HU (2) | HU230044B1 (ko) |
ID (1) | ID29891A (ko) |
IL (3) | IL144852A0 (ko) |
NO (2) | NO328927B1 (ko) |
NZ (1) | NZ513716A (ko) |
PL (2) | PL197158B1 (ko) |
PT (1) | PT1609505E (ko) |
RU (1) | RU2238725C2 (ko) |
SI (1) | SI1609505T1 (ko) |
SK (2) | SK286203B6 (ko) |
TW (1) | TW513301B (ko) |
WO (1) | WO2000051577A2 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3250563T1 (sl) * | 2015-01-30 | 2022-04-29 | Neurocrine Biosciences, Inc. | Substituirani triazoli in z njimi povezani postopki |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0199262A2 (de) * | 1985-04-18 | 1986-10-29 | Ciba-Geigy Ag | Fluorierte Benzyltriazolverbindungen |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1511195A (en) * | 1976-10-18 | 1978-05-17 | Ici America Inc | Triazole derivatives |
-
2000
- 2000-02-22 TW TW089103041A patent/TW513301B/zh not_active IP Right Cessation
- 2000-02-28 SK SK1225-2001A patent/SK286203B6/sk not_active IP Right Cessation
- 2000-02-28 JP JP2000602045A patent/JP4700195B2/ja not_active Expired - Lifetime
- 2000-02-28 EP EP05018762.4A patent/EP1609505B1/en not_active Expired - Lifetime
- 2000-02-28 PL PL350418A patent/PL197158B1/pl unknown
- 2000-02-28 AU AU34253/00A patent/AU764508B2/en not_active Expired
- 2000-02-28 CA CA002362411A patent/CA2362411C/en not_active Expired - Lifetime
- 2000-02-28 DK DK00912515T patent/DK1156856T3/da active
- 2000-02-28 HU HU1000576A patent/HU230044B1/hu active IP Right Revival
- 2000-02-28 BR BR0008606-1A patent/BR0008606A/pt not_active Application Discontinuation
- 2000-02-28 DK DK05018762.4T patent/DK1609505T3/en active
- 2000-02-28 IL IL14485200A patent/IL144852A0/xx active IP Right Grant
- 2000-02-28 PT PT50187624T patent/PT1609505E/pt unknown
- 2000-02-28 SI SI200031078T patent/SI1609505T1/sl unknown
- 2000-02-28 PL PL382172A patent/PL199660B1/pl unknown
- 2000-02-28 CN CNA2004100120495A patent/CN1636562A/zh active Pending
- 2000-02-28 ES ES00912515T patent/ES2244413T3/es not_active Expired - Lifetime
- 2000-02-28 ES ES05018762.4T patent/ES2441208T3/es not_active Expired - Lifetime
- 2000-02-28 NZ NZ513716A patent/NZ513716A/en not_active IP Right Cessation
- 2000-02-28 RU RU2001126350A patent/RU2238725C2/ru active
- 2000-02-28 SK SK5002-2008A patent/SK286775B6/sk not_active IP Right Cessation
- 2000-02-28 HU HU0302780A patent/HU227602B1/hu unknown
- 2000-02-28 KR KR1020017011098A patent/KR100839765B1/ko active IP Right Grant
- 2000-02-28 CN CNB008044929A patent/CN1195516C/zh not_active Expired - Lifetime
- 2000-02-28 KR KR1020077029858A patent/KR100839766B1/ko active IP Right Grant
- 2000-02-28 AT AT00912515T patent/ATE303179T1/de active
- 2000-02-28 ID IDW00200101864A patent/ID29891A/id unknown
- 2000-02-28 EP EP00912515A patent/EP1156856B1/en not_active Expired - Lifetime
- 2000-02-28 DE DE60022317T patent/DE60022317T2/de not_active Expired - Lifetime
- 2000-02-28 WO PCT/EP2000/001626 patent/WO2000051577A2/en active Application Filing
-
2001
- 2001-08-09 IL IL144852A patent/IL144852A/en not_active IP Right Cessation
- 2001-08-28 NO NO20014180A patent/NO328927B1/no not_active IP Right Cessation
-
2006
- 2006-06-13 HK HK06106764.5A patent/HK1086775A1/xx not_active IP Right Cessation
-
2008
- 2008-02-03 IL IL189190A patent/IL189190A0/en unknown
-
2009
- 2009-08-31 NO NO20092921A patent/NO334104B1/no not_active IP Right Cessation
-
2014
- 2014-02-26 CY CY20141100151T patent/CY1115241T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0199262A2 (de) * | 1985-04-18 | 1986-10-29 | Ciba-Geigy Ag | Fluorierte Benzyltriazolverbindungen |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McDonough Jr et al. | Comparative evaluation of benzodiazepines for control of soman-induced seizures | |
Chase et al. | Donepezil plus solifenacin (CPC-201) treatment for Alzheimer's disease | |
CN102307895A (zh) | 用于治疗或预防麻醉药停药症状的方法和组合物 | |
EP2429518A1 (en) | Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors | |
Goldberg | Emerging low-density lipoprotein therapies: microsomal triglyceride transfer protein inhibitors | |
CN107835695A (zh) | 用于治疗自闭症的组合物和方法 | |
EP2705841A1 (en) | Combinations of nootropic agents for treating cognitive dysfunctions | |
JP2017533276A (ja) | 認知低下を処置するための方法 | |
KR20120046795A (ko) | 신경퇴행성 또는 신경근 퇴행성 질환의 치료 방법 및 이러한 질환들을 치료하기 위한 치료제 | |
Browne et al. | Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression | |
US8703762B2 (en) | Method of treating organophosphorous poisoning | |
KR100839766B1 (ko) | 신경통 및 정동 또는 주의력 장애 치료용 플루오르화트리아졸의 용도 | |
KR20120106671A (ko) | 혈중 화학 물질을 제거하기 위한 방법 및 투약 요법 | |
Leccese et al. | The anticonvulsant and behavioral effects of phencyclidine and ketamine following chronic treatment in rats | |
O’Malley et al. | Naltrexone in the treatment of alcohol dependence: Preliminary findings | |
US20190175599A1 (en) | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain | |
WO2012145013A1 (en) | Methods for treating or preventing alcohol-related disorders or craving-related disorders | |
Morgan et al. | Morphine restores and naloxone-precipitated withdrawal depresses wheel running in rats with hindpaw inflammation | |
Bozorgi et al. | Antidepressant-like and memory-enhancing effects of the N-type calcium channel blocker ziconotide in rats | |
RU2203055C2 (ru) | Применение 1-ар(алк)илимидазолин-2-онов для лечения состояния страха и напряженности | |
CA3023439A1 (en) | Treatment of alcoholism and depression and/or dysphoric mood using ibudilast | |
KR101895554B1 (ko) | 올레아놀릭산을 포함하는 신경발달장애 또는 강박장애의 예방, 개선 또는 치료용 조성물 | |
JP2022542145A (ja) | 神経変性障害の処置のための銅複合体 | |
CA2622541C (en) | Use of fluorinated triazoles for treating neuropathic pain | |
RU2304977C2 (ru) | Способ коррекции нестабильности генома у детей с детским церебральным параличом |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130522 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140521 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150519 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160517 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170601 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180529 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190530 Year of fee payment: 12 |